Skip to main content

Teva Pharmaceutical Value Stock - Dividend - Research Selection

Teva pharmaceutical

ISIN: US8816242098 , WKN: 883035

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment\'s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Johnson & Johnson: Why I See Downside Ahead

2026-04-17
Further inthis article, you'll learn about additional reasons why I believe Johnson &Johnson's risk/reward profile is still unattractive. Click for this JNJ update.

FDA Takes Step Forward on Testosterone Therapy for Men

2026-04-16
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy

2026-04-13
Teva shifts from generics to branded specialty, biosimilars and Duvakitug phase 3 upside. Read here for an analysis of TEVA stock.

B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

2026-04-09
B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $38 to $42.

Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

2026-04-01
Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.

FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation

2026-03-31
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda

Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)

2026-03-30
Corcept Therapeutics wins early FDA approval for Lifyorli in platinum-resistant ovarian cancer, boosting growth outlook. Click here for this CORT stock update.

Teva Pharmaceutical Receives FDA Approval For PONLIMSI As Biosimilar To Prolia, And Application For Biosimilar To Xolair

2026-03-30
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United

Tracking David Einhorn's Greenlight Capital Portfolio - Q4 2025 Update

2026-03-22
Greenlight Capital’s Q4 2025 13F: portfolio up to $2.85B, top buys/sells, new stakes, and biggest holdings like GRBK & BHF.

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms

2026-03-17
Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this SYRE stock update.